Xist in X chromosome inactivation: mechanisms and disease relevance Authors: Xiaona Zhang, Qie Mu, Jing Wang, Yuqing Sun, Rui Cao, Lixiao Guo, Qi Han, Jiaojiao Gao, Baofeng Yu, Xiuwei Wang, Li Zhang, Huaxing Meng Published: 2025 ABSTRACT X-inactive specific transcript (Xist) is a main regulator of X chromosome inactivation in mammals, which silences most genes on X chromosome in a cis way. Xist is a kind of lncRNA, which cannot encode the transcript of protein. In addition, Xist RNA mediates the X chromosome inactivation (XCI) process to achieve dose compensation between the sexes. Recent studies have identified that Xist RNA regulates gene expression by recruiting factors/complexes to modify potential chromatin, which were involved in diseases such as neuroinflammation, autoimmune diseases and cancers. In this paper, the research progress of Xist RNA causing a series of diseases in mammalian cells is reviewed, which makes it a potential target for treating human diseases and provides a new direction for further study of diseases. Introduction The long non-coding RNA (lncRNA) is an important class of regulatory molecule, more than 200 nucleotides in length, which plays key roles in a variety of biological processes, such as the regulation of gene expression, cell differentiation and development. Among the many LncRNAs, X-inactive specific transcript (Xist) is a typical representative molecule and is essential for the initiation, establishment and maintenance of X chromosome inactivation (XCI) [1–5]. XIST/Xist RNA expression and XCI usually occur in the early stage of embryonic development, which is very important for normal organ formation and development. It was found that XIST/Xist RNA not only plays a role in the XCI process, but also affects the efficiency of stem cell establishment and quality of the embryo [6]. Therefore, understanding the specific role of XIST/Xist RNA in XCI is important for embryonic development and diseases. X-chromosome inactivation X-chromosome inactivation (XCI), also known as the dosage compensation mechanism, is the process by which an X chromosome is randomly placed in a state of transcriptional silence in female mammals in order to balance the amount of gene expression between the sexes. This phenomenon was first discovered in the 1950 s by Mary F. Lyon while studying the inheritance of coat color in mice [7]. XCI, which usually occurs early in embryonic development, is a permanent epigenetic change that causes the deactivated X chromosome to exhibit a tight chromatin structure and suppresses gene expression. The silencing of inactivated X chromosome can be observed at the cellular level by special staining techniques, such as the inactivated X chromosome showing features of heterochromatin [8]. The XCI consists of initiation, establishment, and maintenance. In mice, initiation of XCI occurs in the ectoderm on embryonic days 4.5–5.5 (E4.5–5.5.5) [9]. In humans, initiation of XCI occurs at the blastocyst stage approximately 4 to 6 days after fertilization. During this process, one of the two X chromosomes in each embryonic cell is randomly inactivated, creating an inactive X chromosome (Xi) and an active X chromosome (Xa). This randomization ensures that the expression of X chromosome genes in cells in the female body is roughly equivalent to that of males (Figure. 1 A). Subsequently, the transcriptional silencing state is established, and the cell enters the maintenance stage of XCI, in which the same X chromosome is propagated as Xi in the subsequent cell division [9]. Abnormal Xist expression has been associated with a variety of diseases including neuroinflammation, autoimmune diseases, and cancers, all of which emphasize the importance of Xist in maintaining homeostasis of gene expression and disease development. Fig. 1Differences between human and mouse XCI processes and XIST/Xist structures. (A) In human, the Xist genes of paternal X chromosome (XP) and maternal X chromosome (XM) will be expressed synchronously for a short time, and then one of them will be randomly selected to continue to be highly expressed and complete XCI, so there is no strict paternal-specific silence like that of mice, showing the different characteristics of “short-term co-expression of two alleles-random single reservation”. However, in mouse, when X chromosome inactivation (XCI) is started, the Xist gene of the paternal X chromosome (Xp) will be fully activated and wrap the whole chromosome, while the Xist gene of the maternal X chromosome (Xm) is still in a state of inhibition (that is, it remains silent, which is called Xist off), forming a mode of “single expression of parents”, which is called imprinting XCI phenomenon. Then, in the inner cell population, after reactivation, random silence appeared. (B) Local tandem repeats in XIST/Xist RNA. The schematic illustrates the intron/exon structure of human XIST and mouse Xist genes with conserved tandem repeat blocks indicated in different colours. A-F represent different repetitive sequences Differences between human and mouse XCI processes and XIST/Xist structures. (A) In human, the Xist genes of paternal X chromosome (XP) and maternal X chromosome (XM) will be expressed synchronously for a short time, and then one of them will be randomly selected to continue to be highly expressed and complete XCI, so there is no strict paternal-specific silence like that of mice, showing the different characteristics of “short-term co-expression of two alleles-random single reservation”. However, in mouse, when X chromosome inactivation (XCI) is started, the Xist gene of the paternal X chromosome (Xp) will be fully activated and wrap the whole chromosome, while the Xist gene of the maternal X chromosome (Xm) is still in a state of inhibition (that is, it remains silent, which is called Xist off), forming a mode of “single expression of parents”, which is called imprinting XCI phenomenon. Then, in the inner cell population, after reactivation, random silence appeared. (B) Local tandem repeats in XIST/Xist RNA. The schematic illustrates the intron/exon structure of human XIST and mouse Xist genes with conserved tandem repeat blocks indicated in different colours. A-F represent different repetitive sequences Structure of XIST/Xist Xist RNA was one of the first long noncoding RNAs (lncRNAs) discovered in the early 1990 s [1, 2, 10, 11]. It does not encode proteins, but rather produces a lncRNA that plays an important role in cell growth and embryonic development. The length of human XIST RNA is approximately 19 kb, located at the X chromosome inactivation center of chromosome Xq13.2. The length of mouse Xist RNA is approximately 17 kb, located at a position of approximately 46.15 cm on the X chromosome. XIST/Xist contains multiple exons and introns and has a complex secondary and tertiary structure. In mice, Xist RNA has seven exons with repetitive regions scattered throughout, labeled A-F [2, 12, 13]. In humans, XIST RNA has six exons with repetitive sequences scattered throughout, also labeled A-F (Figure. 1B). These repetitive regions are associated with localization and silencing of the X chromosome [14–16]. In both the human XIST and mouse Xist models, repeat sequences A and E are included and they are similarly located in the genes and both are highly conserved, whereas repeat sequences B and F are less conserved [17, 18]. Repeat sequence A is associated with localization of XIST RNA in human XIST, whereas repeat sequence E is associated with localization of XIST/Xist RNA in both human XIST and mouse Xist [4, 19–23]. The function of repeat sequence A in human XIST appears to be related to the formation of XIST RNA clouds and less to the maintenance of XCI [18]. In contrast, repeat sequence A in mouse Xist is essential for the maintenance of XCI [13]. Thus, there are some similarities and differences between the repeat sequences of human XIST and mouse Xist in terms of location, number, conservation, and function. The function of repeat sequence D in human XIST and mouse Xist is unknown. These similarities and differences may reflect differences in the mechanisms of human and mouse XCI [18] (Table 1).Table 1The comparison of the characteristics between Xist in mouse and XIST in humanFeature CategoriesMouse XistHuman XISTStructureNameinactive X specific transcriptsX inactive specific transcriptOrganismMus musculusHomo sapiensChromosomal locationX 46.15 cMXq13.2Size~ 17 kb~ 19 kbNumber of Exons76Functional DomainsIt contains six conservative functional domains, such as Rep A, Rep B, Rep C, Rep D, Rep E and Rep F. Among them, Rep A is important for initiating silence, and Rep E is important for RNA localization.It contains six functional domains such as A-F, and the functions of A domain and E domain are evolutionarily conservative. However, there are species differences in specific sequences and structures. For example, human XIST has one more Bh domain than mouse Xist.Functional CharacteristicsActivation Time of XCIThe imprinting inactivation of paternal X chromosome began in the early stage of female embryo development, and then it was reactivated in the inner cell mass of blastocyst and random inactivation was established.In the pre-implantation development stage, both X chromosomes remain active. Although XIST RNA expresses and wraps chromosomes, it does not initiate silencing. XCI was gradually established after blastocyst stage.The Existence of the Imprint XCIIn extra-embryonic tissues such as placenta, paternal X chromosome is inactivated by preferential imprintingNo imprinting inactivation of paternal X chromosome was found in human extraembryonic tissues, and all were randomly inactivated.XCI ModeExtraembryonic tissue: imprinting inactivation (paternal Xi)Embryonic tissue: random inactivationAll tissues: all were randomly inactivated.Gene InteractionsInteraction with Antisense Transcript TSIX/TsixTsix is necessary to inhibit the expression of maternal Xist allele in placental tissue, and Tsix helps to protect maternal X from the inactivation of imprinting X where the paternal X chromosome is preferentially silencedTSIX is not involved in genome imprinting, and may not be an antagonist of human XIST expressionInteraction with Protein FactorsAt the beginning of XCI, Xist recruited SPEN through A repeats to promote deacetylation of histones [26]. Subsequently, the B and C repeats of Xist were combined with hnRNPK to recruit Polycomb inhibitory complexes (PRC)1 and 2, which were responsible for the late accumulation inhibitory markers H2AK119b and H3K27me3, respectively, to further lock the silent state [26]. RBM15 will recruit m6A RNA methylation mechanism to Xist after combining with the A- repeat sequence of Xist. M6A locus on Xist will then recruit YTHDC1 reading protein, which is considered to play a role in gene silencing during XCI [26, 27]. HnRNPU is involved in anchoring Xist to chromatin [26]. PTBP1, MATR3, CIZ1, TDP-43 and CELF1 proteins bind to the E repeat of Xist [14].The interaction between the repeated sequence A of XIST and SPEN protein recruits SMRT complex to activate histone deacetylase 3(HDAC3) [28]. SRSF1 mainly binds to A repeat domain [28, 29]. HnRNPK binds the BCD-repeat domain exclusively [28–30]. RBM15 and RBM15B bind to the A repeat region and E repeat domain of XIST to a small extent [27, 28, 30]. HnRNPU is a bridge between XIST RNA and Xi chromosome, which combines BCD and exon 6 domains [28, 30, 31]. CELF1, MATR3 and PTBP1 bind to the E repeat domain of XIST [28–30]. Table 1The comparison of the characteristics between Xist in mouse and XIST in humanFeature CategoriesMouse XistHuman XISTStructureNameinactive X specific transcriptsX inactive specific transcriptOrganismMus musculusHomo sapiensChromosomal locationX 46.15 cMXq13.2Size~ 17 kb~ 19 kbNumber of Exons76Functional DomainsIt contains six conservative functional domains, such as Rep A, Rep B, Rep C, Rep D, Rep E and Rep F. Among them, Rep A is important for initiating silence, and Rep E is important for RNA localization.It contains six functional domains such as A-F, and the functions of A domain and E domain are evolutionarily conservative. However, there are species differences in specific sequences and structures. For example, human XIST has one more Bh domain than mouse Xist.Functional CharacteristicsActivation Time of XCIThe imprinting inactivation of paternal X chromosome began in the early stage of female embryo development, and then it was reactivated in the inner cell mass of blastocyst and random inactivation was established.In the pre-implantation development stage, both X chromosomes remain active. Although XIST RNA expresses and wraps chromosomes, it does not initiate silencing. XCI was gradually established after blastocyst stage.The Existence of the Imprint XCIIn extra-embryonic tissues such as placenta, paternal X chromosome is inactivated by preferential imprintingNo imprinting inactivation of paternal X chromosome was found in human extraembryonic tissues, and all were randomly inactivated.XCI ModeExtraembryonic tissue: imprinting inactivation (paternal Xi)Embryonic tissue: random inactivationAll tissues: all were randomly inactivated.Gene InteractionsInteraction with Antisense Transcript TSIX/TsixTsix is necessary to inhibit the expression of maternal Xist allele in placental tissue, and Tsix helps to protect maternal X from the inactivation of imprinting X where the paternal X chromosome is preferentially silencedTSIX is not involved in genome imprinting, and may not be an antagonist of human XIST expressionInteraction with Protein FactorsAt the beginning of XCI, Xist recruited SPEN through A repeats to promote deacetylation of histones [26]. Subsequently, the B and C repeats of Xist were combined with hnRNPK to recruit Polycomb inhibitory complexes (PRC)1 and 2, which were responsible for the late accumulation inhibitory markers H2AK119b and H3K27me3, respectively, to further lock the silent state [26]. RBM15 will recruit m6A RNA methylation mechanism to Xist after combining with the A- repeat sequence of Xist. M6A locus on Xist will then recruit YTHDC1 reading protein, which is considered to play a role in gene silencing during XCI [26, 27]. HnRNPU is involved in anchoring Xist to chromatin [26]. PTBP1, MATR3, CIZ1, TDP-43 and CELF1 proteins bind to the E repeat of Xist [14].The interaction between the repeated sequence A of XIST and SPEN protein recruits SMRT complex to activate histone deacetylase 3(HDAC3) [28]. SRSF1 mainly binds to A repeat domain [28, 29]. HnRNPK binds the BCD-repeat domain exclusively [28–30]. RBM15 and RBM15B bind to the A repeat region and E repeat domain of XIST to a small extent [27, 28, 30]. HnRNPU is a bridge between XIST RNA and Xi chromosome, which combines BCD and exon 6 domains [28, 30, 31]. CELF1, MATR3 and PTBP1 bind to the E repeat domain of XIST [28–30]. The comparison of the characteristics between Xist in mouse and XIST in human Extraembryonic tissue: imprinting inactivation (paternal Xi) Embryonic tissue: random inactivation Furthermore, previous studies have shown that while XIST/Xist acts in concert with other RNAs such as TSIX, XACT to regulate XCI, the underlying mechanisms differ between humans and mice. TSIX is identified as an RNA with reverse transcription to XIST gene, and its 3’ end overlaps with XIST locus. In mouse, Tsix is very important for inhibiting the expression of Xist allele on maternal X chromosome in placental tissue, and it can also protect maternal X chromosome from being affected by the imprinting inactivation mechanism of paternal X chromosome. In human, it exists in embryonic stem cells, and completely absents in adult somatic cells. Studies have shown that human TSIX is not involved in the regulation of genomic imprinting, and may not be an antagonist of XST expression. In addition. TSIX has not established a clear role in maintaining the activity of another X chromosome, which suggests that its function inhuman XCI is far less critical than that in mice, and it may only exist as an evolutionary relic or an auxiliary regulatory element [24]. XACT (X-active coating transcript) is a newly discovered long-chain non-coding RNA in human pluripotent stem cells. Its transcripts are not spliced, but mainly exist in the nucleus, and their RNA FISH (Fluorescence In Situ Hybridization) signals are similar to those of XIST RNA cloud, but they correspond to active X chromosomes. In the absence of XIST expression, XACT is expressed from two X chromosomes in human cells, but not in mouse cells, which indicates that XACT may play a unique role in the initial control of human XCI. In human pluripotent stem cells, the expression of XACT and the phenomenon of covering the active X chromosome are limited to pluripotent cells and early differentiated cells, and gradually become silent during the differentiation process. However, whether XACT will be expressed in some differentiated cell types needs further study. XACT has some similarities with lncRNA Tsix in mice, for example, they both play a role in the inactivation of X chromosome and are species-specific. However, Tsix is mainly expressed in embryonic stem cells of female mice and inhibits the expression of Xist, thus preventing the occurrence of XCI. XACT, however, is mainly expressed in human pluripotent stem cells, and its specific function is not clear, but it may be related to maintaining the activity of active X chromosome [25]. A variety of Xist-RNA-binding proteins, including SPEN, have recently been identified as critical for the initiation of gene silencing in the X chromosome in mouse embryos prior to embryo implantation as well as in embryonic stem cells. Protein interacting with XIST/Xist RNA XIST/Xist RNA regulates the female mammalian XCI by interacting with a variety of proteins such as SPEN, RBM15, hnRNPK (Figure. 2 A). In research, genetic screening techniques are often used to identify novel protein factors that interact with XIST RNA. These screens can confirm the functional relevance of known interactors such as SMC1A, RING1B, YY1, HP1, etc., and identify novel interactors such as SPEN and RBM15 [32]. These newly identified interactors may be critical to the gene silencing ability of XIST RNA. The reason for this interaction is to achieve dosage compensation for gene expression between the sexes and to ensure that only one of the X chromosomes remains active in female individuals. The purposes of XIST/Xist-protein interactions include recruitment of chromatin-modifying complexes, maintenance and propagation of the inactivated state, regulation of gene expression, and regulation of the expression and stability of XIST/Xist itself. These interactions are essential for the precise and stable execution of XCI. Fig. 2XIST/Xist mechanisms of action. (A) Diagram of the mouse genomic XIST/Xist locus with its exons and introns and the location and key binding partners of the XIST/Xist repeat elements A-F. (B) XIST/Xist RNA dissemination occurs primarily during the establishment phase of the XCI. This process involves the binding of XIST/Xist RNA to a variety of proteins that contribute to its distribution on the chromosome. Interaction between mouse Xist repeats and protein: B and C repeats bind to hnRNP-K, which recruits multi-comb inhibitory complexes (PRC)1 and 2 that deposit histone markers H3K27me3 and H2AK119Ub1 to lock the silent state. The A repeat sequence of Xist interacts with SPEN, which is very important for silencing almost all genes. RBM15 will recruit m6A RNA methylation mechanism to Xist after combining with the A- repeat sequence of Xist. M6A locus on Xist will then recruit YTHDC1 reading protein, which is considered to play a role in gene silencing during XCI. Interaction between human XIST repeats and protein: HnRNPK is needed for PRC1 and PRC2 to recruit Xi. However, so far, there is no evidence that there is a direct interaction between HnrnpK and PRC complex, so it is not clear how this happens. SPEN binds the A repeats of human XIST, and recruits SMRT-HDAC3 complexes to inhibit transcription. RBM15 and RBM15B are the key linkers for bringing WTAP-containing methyltransferase complex into XIST RNA, which indicates that this function is mediated by m6A reader YTHDC1 XIST/Xist mechanisms of action. (A) Diagram of the mouse genomic XIST/Xist locus with its exons and introns and the location and key binding partners of the XIST/Xist repeat elements A-F. (B) XIST/Xist RNA dissemination occurs primarily during the establishment phase of the XCI. This process involves the binding of XIST/Xist RNA to a variety of proteins that contribute to its distribution on the chromosome. Interaction between mouse Xist repeats and protein: B and C repeats bind to hnRNP-K, which recruits multi-comb inhibitory complexes (PRC)1 and 2 that deposit histone markers H3K27me3 and H2AK119Ub1 to lock the silent state. The A repeat sequence of Xist interacts with SPEN, which is very important for silencing almost all genes. RBM15 will recruit m6A RNA methylation mechanism to Xist after combining with the A- repeat sequence of Xist. M6A locus on Xist will then recruit YTHDC1 reading protein, which is considered to play a role in gene silencing during XCI. Interaction between human XIST repeats and protein: HnRNPK is needed for PRC1 and PRC2 to recruit Xi. However, so far, there is no evidence that there is a direct interaction between HnrnpK and PRC complex, so it is not clear how this happens. SPEN binds the A repeats of human XIST, and recruits SMRT-HDAC3 complexes to inhibit transcription. RBM15 and RBM15B are the key linkers for bringing WTAP-containing methyltransferase complex into XIST RNA, which indicates that this function is mediated by m6A reader YTHDC1 During XCI, XIST/Xist RNA interacts with different RNA-binding proteins (RBPs) through specific structural domains to form the XIST/Xist RNA protein complex [27], which exercises different functions and plays a key role in inhibitory modifications (histone deacetylation, histone methylation, and DNA methylation). For example, the repeated sequence A of XIST RNA can directly interact with hnRNP-U, SPEN/SHARP protein, RBM15/RBM15B, or directly bind to the catalytic subunit EZH2 of PRC2 [4, 33, 34]. The interaction of XIST RNA with these proteins is primarily aimed at achieving X-chromosome dosage compensation in female mammals, which maintains genomic homeostasis by recruiting chromatin-remodeling complexes, promoting gene silencing, stabilizing XIST RNA and ensuring that it is correctly localized to the inactivated X chromosome, which in turn triggers chromatin condensation and gene expression repression. hnRNP-U(SAF-A) HnRNP-U (also known as SAF-A) is the key ankyrin of XIST, which is responsible for recruiting XIST and stably binding it to the inactivated X chromosome (XI) region, thus initiating and maintaining X chromosome inactivation (XCI) [35]. In human RPE-1 cells, acute removal of hnRNP-U will significantly increase the number of XIST RNA foci, indicating that its localization is impaired, accompanied by a significant decrease in the levels of H2AK119ub and H3K27me3 on XI, suggesting that hnRNP-U is essential to XIST-mediated chromatin silencing [35]. The N-terminal SAP domain of hnRNP-U and its phosphorylation sites S14/S26 play a critical role in maintaining the correct localization of XIST RNA on XI and the histone modification dependent on XIST. The deletion or mutation of these sites will significantly weaken the function of XIST [35]. At the evolutionary level, hnRNP-U, as the core member of XIST interaction group, is highly conservative in different mammals. Although there are differences in XCI mechanism among species, the interaction between hnRNP-U and XIST is always considered as the key node [36]. HnRNP-U binds to various RNAs (including XIST) in a redundant way through its two RGG/RG motifs at the C-terminal. Although the affinity of a single motif is low, the synergy can achieve high affinity binding to RNAs such as XIST [37]. SPEN/SHARP/MINT SPEN (also known as SHARP in humans and MINT in mice) is an RNA-binding protein with a molecular weight of approximately 400 kDa, with four N-terminal RNA recognition motifs (RRMs) and a highly conserved C-terminal SPOC structural domain, which is capable of recruiting different proteins involved in transcriptional silencing, and plays an important role in the early stages of XCI [4]. SPEN protein is not only involved in gene silencing, but also promotes the stable expression of Xist RNA, which is required for Xist RNA localization [38–41]. SPEN is a key coordinator in the initiation of gene silencing on the X chromosome, particularly in the early embryo and embryonic stem cells of the mouse. SPEN mediates gene silencing by binding to Xist RNA through its SPOC structural domain. SPEN is also immediately recruited to the X chromosome, where it is localized to enhancers and promoters of active genes as Xist is up-regulated [41, 42]. In mouse embryonic stem cells, the repeat sequence A of Xist RNA recruits SMRT complexes through direct interaction with the SPEN protein, activates histone deacetylase 3 (HDAC3), and through histone deacetylation, rejects RNA polymerase Pol Ⅱ on the inactive X chromosome, thereby inhibiting transcription [32, 43] (Figure. 2B). Once gene silencing is completed, the SPEN protein rapidly dissociates from chromatin, but its binding to XIST/Xist RNA persists. These studies have proved that SPEN protein plays a key role in the start-up stage of XCI, ensuring the smooth progress of XCI [4, 33, 34, 41, 42, 44, 45]. Although SPEN has been shown to be a key player in Xist-mediated silencing, the exact molecular mechanisms by which it contributes to the establishment and/or maintenance of gene silencing remain elusive. RBM15 and RBM15B RNA-binding motif protein 15 (RBM15) is a protein belonging to the SPEN family with three RNA-binding structural domains and a SPOC structural domain located at the carboxyl terminus [4]. RBM15 is involved in the process of Xist RNA propagation [42]. It was found that in human cells, XIST contains at least 78 N6-methyladenosine (m6A) residues [27]. The formation of m6A requires RBM15 and its cognate protein RBM15B. RBM15/15B, binding to the A-repeat sequence of XIST, is able to recruit and bind the m6A methylation complex to the XIST RNA-specific site, resulting in adenosine nucleotide methylation at the adjacent site. In addition, m6A residues in XIST recruit YTH domain protein 1 (YTHDC1), which is required for XIST function (Figure. 2B). Artificial ligation of YTHDC1 to XIST rescues XIST-mediated gene silencing in the absence of m6A. These data reveal that the m6A formation and recognition pathway are critical for XIST-mediated transcriptional silencing. The study confirms that RBM15 and m6A play relatively minor roles in XIST-mediated silencing [4, 27]. HnRNPK Heteronuclear ribonucleoprotein K (hnRNPK) has a relative molecular weight of approximately 66 kDa and consists mainly of three K homology domains (KH1, KH2, and KH3), a K-protein-interacting region (KI), and a C-terminal protein kinase-binding domain [46]. It was found that hnRNPK contributes to Xist-mediated chromatin modification and Polycomb recruitment, but is not required for lncRNA Xist localization [17, 33, 38, 40]. Thus, there are many factors that contribute to how hnRNPK affects Xist-mediated silencing. The Polycomb system consists of several multi protein complexes that catalyze histone modifications of H2AK119ub1 (classical and variant PRC1 complex) and H3K27me3 (PRC2 complex), recruiting Xi in a Xist RNA-dependent manner [4, 33] (Figure. 2B). The classical PRC1 complex contains Ring1A/B and CBX (also known as PCGF) proteins, which together catalyze H2AK119ub1. Variant PRC1 complexes are similar to classical PRC1, but they contain different PCGF family members (PCGF2/4/6/7) and different CBX proteins. These variant complexes are also able to catalyze the modification of H2AK119ub1. The PRC2 complex contains proteins such as Ezh1/2 (histone methyltransferase), SUZ12, and EED, which is responsible for catalyzing the trimethylation of the lysine at position 27 of histone H3 (H3K27me3) [47, 48]. One study, by analyzing CRISPR/Cas9 knockdown of Xist RNA in mice, found that the repetitive sequence B/C is responsible for the recruitment of the polycomb system, which, by interacting with hnRNPK, is essential for the spreading of Xist RNA and for the maintenance of PRC1/PRC2 function on the inactivated X chromosome (Xi) [49]. Surprisingly, deletion of the repetitive sequence B/C disrupts PRC1 and PRC2 recruitment. Conversely, disruption of PRC1 or PRC2 impairs Xist spreading. The PRC2 complex is responsible for depositing the H3K27me3 marker on the X chromosome, a key epigenetic modification that maintains XCI. H3K27me3 tagging will serve as a recruitment anchor for the CBX (chromoBox homolog) subunit of typical PRC1, thus enhancing PCG-mediated Xi heterochromatinization [50]. This study confirms that the repetitive sequence B/C integrates interdependent Xist/polycomb propagation, silencing and chromosomal structure [4, 17, 33, 46, 50, 51]. It has reported that hnRNPK self-assembled into liquid-liquid separation (LLPS) aggregates through its RGG domain, and then the RepB motif of Xist RNA combined with it to “soften” the aggregates and enhance the deformability, adhesion and wettability, thus internalizing and enriching silencing factors such as Xist and PRC1, driving Xist to spread along the X chromosome in a cis way and establishing an inactivation center, thus realizing X chromosome inactivation [52]. XIST/Xist is responsible for triggering XCI in female mammals. This process relies on the interaction of a series of XIST/Xist activators and repressors, where activators such as YY1 positively regulate XIST/Xist expression by binding to the promoter region of the XIST/Xist gene and promoting chromatin remodeling and transcription initiation. On the other hand, repressors such as OCT4 can inhibit XIST/Xist expression through direct binding to the promoter or enhancer region of the XIST/Xist gene, thereby affecting the XCI process. XIST/Xist activators and XIST/Xist repressors XIST/Xist activators and repressors are transcription factors that regulate the expression of XIST/Xist genes and play a key role in the XCI process. XIST/Xist activators such as YY1, RIF1, KDM5C, GATA, FTX, JPX, RNF12/RLIM, etc. enhance gene transcription by binding to enhancers or other regulatory regions of the genes and recruiting co-activators and chromatin remodeling complexes (Fig. 3). XIST/Xist repressors such as Tsix, OCT4, CTCF, PRDM14, REX1, NANOG, etc. recruit co-repressors that induce chromatin contraction by binding to anechoic or other regulatory regions of XIST/Xist genes, thereby reducing transcription of XIST/Xist genes (Fig. 3). Fig. 3The X-chromosome Inactivation Center. The XIC is located at ~103 Mb on the mouse X chromosome (mm10). It contains several lncRNAs, such as Linx, Tsx, Xite, Tsix, Xist, Jpx, Ftx, and Xert, and several coding genes, such as Nap1L2, Cdx4, Chic1, Slc16a2, and Rnf12. Xist and Tsix are two antisense genes at the center of the XIC. The X-chromosome Inactivation Center. The XIC is located at ~103 Mb on the mouse X chromosome (mm10). It contains several lncRNAs, such as Linx, Tsx, Xite, Tsix, Xist, Jpx, Ftx, and Xert, and several coding genes, such as Nap1L2, Cdx4, Chic1, Slc16a2, and Rnf12. Xist and Tsix are two antisense genes at the center of the XIC. XIST/Xist activators YY1 YY1, encoded by a 23 kb YY1 gene, is a GLI-Krüppel-like protein that can bind DNA to four Cys2His2(Cysteine at positions 2 and Histidine at positions 2 zinc finger domain) zinc fingers at the C-terminal of protein [53]. YY1 is the first autosomal activator found to regulate Xist transcription and has an important role in the conserved mechanism of XCI [53]. During XCI in mouse embryonic stem cells (mESCs), YY1 triggers the activity of the promoter 2 of Xist by binding to the 5’ region of Xist, confirming that YY1 promotes Xist expression [54]. YY1 and regulator of X-chromosome transcription 1(REX1) were found to bind competitively to the 5’ region of the Xist gene, and REX1 protein accumulation inhibited YY1 binding, resulting in impaired Xist expression. This confirms the activating effect of YY1 on Xist expression and reveals an important role for REX1 as a Xist repressor in XCI [54]. It has also been demonstrated that XCI has been found to lead to the formation of two giant interactions domains in X-chromosomes, in which escape genes form TAD structures on X-chromosomes and are associated with CTCF-binding sites in neural progenitor cells and embryonic stem cells of mice. Thus, gene expression and CTCF binding are critical for the formation of TAD structures on X chromosomes and reveal a key role for Xist RNA in the process of X chromosome inactivation [55]. RIF1 RIF1 (replication time regulator 1) is a major regulator of replication time (RT) in human cells. The molecular weight of the human RIF1 protein is 274,466 kDa [56]. The structure of the RIF1 protein consists of three major structural domains: the N-terminal structural domain (NTD), the C-terminal structural domain (CTD), and an intermediate region. These domains play an important role in the function of RIF1. For example, the N-terminal domain binds to G4 (Guanine Quadruplex)-quadruplex structure, while the C-terminal domain interacts with various protein, and participates in various biological processes such as DNA damage response, cell cycle regulation and chromatin remodeling. It was found that during differentiation of mESCs, the rise of Tsix RNA weakens the binding of RIF1 to the promoter of the Xist gene, leading to asymmetric binding of RIF1 to the inactivated Xi chromosome and promoting the up-regulated expression of the Xist gene. On the Xa chromosome without RIF1, the combination of KAP1 promoted the continuous high-level expression of Tsix and maintained the rejection of RIF1, thus forming a self-reinforcing stable state and transforming random events into a stable inherited X chromosome state. This study confirms the important role of RIF1 and KAP1 in the process of XCI [57]. KDM5C KDM5C (Lysine Demethylase 5 C) is a protein-coding gene that belongs to the SMCY homologous family. Its protein contains an ARID structural domain, a JmjC structural domain, a JmjN structural domain and two PHD-type zinc finger structures. These structural domains suggest that the protein is involved in the regulation of transcription and chromatin remodeling. As we all know, KDM5C is one of the genes that escape the inactivation of X chromosome, and it is more expressed in female cells [58]. KDM5C encodes a demethylase that enhances Xist RNA expression by converting the H3K4me2/3 modification on histone H3 to H3K4me1. Overexpression of KDM5C in mouse and human embryonic stem cells induced Xist expression, whereas KDM5D, a homologous gene on the Y chromosome, did not. This suggests that the KDM5C function that activates Xist is highly conserved in eumetazoa and predates the separation of eumetazoa and marsupial mammals [58]. GATA GATA transcription factors are a class of proteins that are widespread in eukaryotes, and they play important roles in a variety of biological processes. One study identified the GATA family of transcription factors as strong activators of the Xist gene through a CRISPR activation screen, and they were able to directly activate Xist expression. GATA family members GATA1, GATA2, GATA3, GATA4, GATA5, and GATA6 are all capable of inducing Xist expression in mESCs. Further analysis revealed that GATA6 activates Xist expression by directly binding to the enhancer element RE79 about 100 kb upstream of the Xist gene. During animal embryonic development, GATA factors are expressed in early embryos, while Xist genes are also upregulated in early embryos. Upon knockdown of GATA1/4/6 or the GATA-binding Xist enhancer element RE79/97, Xist expression in early embryos can be significantly reduced. Thus, the study confirms that the GATA factor plays a key role for the first up-regulation of Xist during embryonic development [59]. FTX Ftx is a noncoding gene located at the X chromosome inactivation center (Xic) in mice. It does not encode protein, but produces many nuclear long-chain noncoding RNA (lncRNA) isomers. Ftx regulates the expression of Xist through its transcription activity in cis position, rather than the long-chain noncoding RNA (lncRNA) or embedded microRNA. Specifically, the transcription event itself (but not the transcription product) in Ftx promoter region is necessary to activate the transcription of Xist, which is independent of the RNA product of Ftx or the binding site of CTCF, and mainly promotes the transcription activation of Xist through transcription activity, thus initiating X chromosome inactivation (XCI) [60]. JPX Jpx is a long-chain noncoding RNA (lncRNA) located in the X chromosome inactivation center (XIC) region, which plays an important role in regulating Xist expression and X chromosome inactivation. Jpx releases the inhibition of CTCF on Xist promoter by competitively binding CTCF protein, thus promoting the transcription of Xist, and finally causing X chromosome inactivation [61]. RNF12/RLIM In the early embryos of female mice, X-linked E3 ubiquitin ligase Rlim (Rnf12) released the inhibition of Xist by targeted degradation of transcription inhibitor Rex1 (Zfp42), thus initiating X chromosome inactivation (XCI). In the pre-blastocyst stage (iXCI) after fertilization, Rlim is highly expressed, which continuously degrades Rex1, enabling Xist to activate and silence the paternal X chromosome. This regulatory axis is essential to maintain the identity of ectotrophoblast progenitor cells (pTE). However, after blastocyst implantation, the expression of Rex1 in epiblast cells was down-regulated in an Rlim-independent way, which made the Rlim-Rex1 axis inactive in this lineage, thus allowing the random XCI (rXCI) to proceed independently. Therefore, the Rlim-Rex1 axis only regulates Xist in extraembryonic tissues, ensuring the precise coordination between X dose compensation and cell fate determination [62]. XIST/Xist repressors Tsix Tsix is an antisense transcript of Xist gene, which is located downstream of Xist and partially overlaps with it, and plays a key negative regulatory role in the process of X chromosome inactivation (XCI). In embryonic stem cells (mESCs), Tsix is highly expressed on both X chromosomes, which inhibits the transcriptional activity of Xist through transcriptional interference mechanism and prevents its premature activation. The expression of Tsix is regulated by several cis-regulatory elements, including Xite enhancer, which maintains the independence of TAD-D region where Tsix promoter is located through CTCF binding site and prevents Xist promoter from being affected by activating factors in this region. With the differentiation of cells, Tsix is gradually down-regulated on one X chromosome, which releases the inhibition of Xist, so that Xist can be specifically up-regulated on the future inactivated X chromosome to form RNA clouds and start XCI. The continuous expression of Tsix will interfere with the function of Xist, which will lead to the damage of Xist RNA cloud formation, and then affect the normal startup of XCI. Therefore, Tsix precisely regulates the spatio-temporal expression of Xist through the isolation between its antisense transcript and TAD domain, and ensures the normal progress of XCI [63]. OCT4 OCT4 (Octamer-binding protein 4) is a transcription factor with a molecular weight of approximately 38 kDa that plays a key role in early mammalian development and stem cell maintenance [64]. In mESCs, OCT4 was found to bind to the non-coding RNA genes of two X chromosome silencing centers, Tsix and Xite. the expression products of Tsix and Xite inhibit the expression of XIST, thus blocking XCI. OCT4 also directly binds to and inhibits the expression of the XIST gene. Through the dual mechanism of activating Tsix/Xite and repressing XIST, OCT4 finely regulates the process of X-chromosome inactivation, thereby maintaining cellular pluripotency and participating in epigenetic reprogramming. Taken together, OCT4 is the first transcription factor identified to regulate X-chromosome counting, linking cell differentiation to X-chromosome programming by multifaceted regulation of XCI processes [65]. CTCF CTCF (CCCTC-binding factor) is a DNA-binding protein containing 11 zinc finger structures that directly binds and represses the promoter 2 region of the Xist gene [66, 67]. In mESCs, CTCF was found to bind directly to the promoter 2 region of the Xist gene and repress Xist expression. This confirms the role of CTCF as a repressor of Xist and forms a functional antagonistic relationship with Jpx RNA to co-regulate Xist transcription [68]. It was also found that CTCF can distinguish between active and inactive X and interacts with some lncRNAs such as Tsix, Xite and Xist. These RNAs can recruit CTCF to specific genomic regions by cis-acting to regulate X chromosome pairing [69]. PRDM14 PRDM14 (PR-domain containing protein 14) is a transcriptional regulator belonging to the PRDM (PRDI-BF1 and RIZ homology domain containing) family, and members of this family usually have histone methyltransferase activity, which is essential for the establishment of pluripotency in mESCs and primordial germ cells (PGCs) are critical for the establishment of pluripotency [70, 71]. In mouse cells, PRDM14 was found to be essential for X chromosome reactivation (XCR) and also plays a key role in the self-renewal and maintenance of induced pluripotent stem cells (iPSC). This finding confirms the function of PRDM14 in XCR and cell reprogramming and provides a framework for future studies of epigenetic stability and quality of iPSCs [72]. REX1 (also known as P-Rex1) is a multi-structural domain protein that plays a role in neuronal cells especially in regulating neurite growth [73]. In mESCs, RNF12/RLIM (Ring finger protein 12/RNA-binding motif and Lin-28 domain containing 1) was found to activate XCI by degrading REX1 through ubiquitination. This study confirms that RNF12/RLIM plays an important role in XCI initiation and provides new insights into understanding the regulatory mechanism of XCI. NANOG is a key transcription factor for maintaining pluripotency in embryonic stem cells and negatively regulates XIST expression [74]. In mouse embryonic stem cells (ESCs) and embryos, NANOG has been found to bind to the Xist motif and repress Xist expression, thereby maintaining X chromosome activity. Deletion of NANOG leads to elevated Xist expression and triggers XCI, confirming the important role of NANOG in maintaining X chromosome activity [75]. XIST/Xist RNA and diseases XIST/Xist is a long-stranded non-coding RNA whose primary function is dosage compensation of X chromosome gene expression by covering the X chromosome and inducing its inactivation in female mammals. When XIST/Xist functions abnormally, it leads to disruption of the X chromosome inactivation process, affecting gene expression and chromatin remodeling, which in turn causes a number of neuroinflammation (autism spectrum disorders, Down syndrome, autism spectrum disorders, schizophrenia, and Rett syndrome), autoimmune diseases, and other diseases (Fig. 4). Fig. 4Mechanisms of XIST in Disease. XIST is closely related to the occurrence and development of many diseases. XIST inhibits the expression of neprilysin (NEP, the main Aβ degrading enzyme in the brain) through epigenetic mechanism, which leads to the obstruction of Aβ clearance, thus promoting Aβ accumulation and neuroinflammation. XIST mediates the activation of NF-κB pathway through miR-122-5p/PKCh axis, which aggravates sepsis-related neuroinflammation. By competitively binding to miR-320a, XIST can release its inhibition on PIK3CA, activate PI3K/AKT pathway, promote the proliferation, invasion and migration of hepatocellular carcinoma cells, and inhibit apoptosis. As a competitive endogenous RNA, XIST adsorbs miR-34a, relieves its inhibition on MET, activates MET-PI3K-AKT pathway, and promotes cell proliferation and tumor growth. XIST activates the immune system through its RNA- protein complex (XISRNP) as a "female-specific antigen", which is the key driving factor for the high incidence of autoimmune diseases in women Mechanisms of XIST in Disease. XIST is closely related to the occurrence and development of many diseases. XIST inhibits the expression of neprilysin (NEP, the main Aβ degrading enzyme in the brain) through epigenetic mechanism, which leads to the obstruction of Aβ clearance, thus promoting Aβ accumulation and neuroinflammation. XIST mediates the activation of NF-κB pathway through miR-122-5p/PKCh axis, which aggravates sepsis-related neuroinflammation. By competitively binding to miR-320a, XIST can release its inhibition on PIK3CA, activate PI3K/AKT pathway, promote the proliferation, invasion and migration of hepatocellular carcinoma cells, and inhibit apoptosis. As a competitive endogenous RNA, XIST adsorbs miR-34a, relieves its inhibition on MET, activates MET-PI3K-AKT pathway, and promotes cell proliferation and tumor growth. XIST activates the immune system through its RNA- protein complex (XISRNP) as a "female-specific antigen", which is the key driving factor for the high incidence of autoimmune diseases in women XIST/Xist RNA and neuroinflammation The high incidence of Alzheimer’s disease (AD) in women has always been an unsolved mystery in the field of neuroscience, and some studies have clearly suggested that X chromosome is related to the risk of AD [76]. AD is characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain, leading to nerve cell damage and death, which in turn causes memory loss, cognitive decline, and behavioral changes [77]. The higher incidence of female AD is not only due to the longer life expectancy, but also closely related to the biological characteristics of X chromosome. Studies have shown that individuals with two X chromosomes (such as women) show stronger cognitive resilience and lower mortality in the AD model, partly because some genes on the X chromosome (such as Kdm6a) can escape X chromosome inactivation (XCI), thus expressing higher levels of neuroprotective factors [78]. As the key noncoding RNA to regulate XCI, Xist RNA’s expression in female brain may indirectly regulate the susceptibility to neurodegeneration by affecting the expression profile of X chromosome inactivation escape gene. Therefore, the mechanism of X chromosome inactivation mediated by XIST may be one of the potential biological bases for women to suffer from AD. Studies in AD mouse models and Aβ-induced cellular models revealed increased expression of XIST RNA, which was associated with neuronal cell inflammation and injury in AD mice. XIST RNA affects the expression of the Aβ-degrading enzyme NEP through epigenetic regulation and is negatively correlated with NEP expression. Specifically, XIST RNA regulates NEP expression in part by binding to EZH2, which mediates neuronal inflammation and injury. In short, this study confirms that XIST RNA plays a role in AD by epigenetically inhibiting NEP and inducing Aβ accumulation and neuroinflammation [79]. This indicates that XIST RNA has an undeniable impact on the pathology of AD. XIST RNA may provide new insights for the unclear etiology of AD and the current suboptimal drug treatment. Xist RNA regulates neuroinflammation in periventricular white matter of septic rats through the miR-122-5p/PKCh axis. It was found that miR-122-5p levels were significantly reduced in the cerebrospinal fluid of septic patients, and miR-122-5p expression was also significantly downregulated in the periventricular white matter of septic rats. Further studies revealed that Xist RNA is the upstream target gene of miR-122-5p, while PKCh is its downstream target gene. Overexpression of miR-122-5p or silencing of Xist RNA both significantly reduced neuroinflammation in the periventricular white matter of septic rats. At the cellular level, silencing of Xist RNA increased miR-122-5p expression and decreased PKCh expression, thereby inhibiting microglia and astrocyte activation. Taken together, Xist RNA may be involved in neuroinflammation through the miR-122-5p/PKCh axis [80]. Needless to say, the function of XIST/Xist RNA in neurological diseases is largely unknown and should be explored to identify new therapeutic mechanisms and drug targets. XIST/Xist RNA and autoimmune diseases XIST/Xist not only plays a role in neuroinflammation, but also in autoimmune diseases. Dysregulation of XIST/Xist RNA may lead to increased expression of X chromosome immunity genes in females, thereby increasing the risk of autoimmune diseases [81]. It was found that expression of Xist ribonucleoprotein (RNP) in male mice induced autoantibody production and that Xist RNP was also associated with a variety of autoimmune diseases in female patients. These findings suggest that Xist RNP may be an important contributor to women’s greater susceptibility to autoimmune diseases, providing therapeutic direction for human disease [82, 83]. Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which the immune system mistakenly attacks the body’s normal tissues and organs, resulting in a variety of symptoms such as skin erythema, joint pain, fatigue, and fever. The etiology of SLE is not completely clear, but genetic, environmental and lifestyle factors may all play a role. The pathogenesis of SLE involves abnormal activation of immune system, including the production of autoantibodies (such as antinuclear antibodies), abnormal activation of immune cells and persistence of inflammatory reaction [84]. In B cells from SLE patients, there were differences in the localization patterns of XIST RNA and double allelic expression of immune-related genes, and elevated transcript levels of these genes. This confirms that abnormal maintenance of XCI may lead to enhanced immune function and increased susceptibility to autoimmune diseases in female lymphocytes [85]. Future studies may reveal more specific details about this process and may provide new targets for the treatment of SLE. Taken together, these studies provide important insights into how XIST/Xist RNA may provide therapeutic opportunities for female-biased autoimmune diseases. XIST/Xist RNA and cancers XIST/Xist RNA exhibits aberrant expression in a wide range of cancers and functions as a proto-oncogene in most cases. XIST/Xist RNA plays an important role in several aspects of tumorigenesis, progression and prognosis. XIST shows high expression in male cancers, while XCI, a process that usually occurs only in female (XX) cells, balances gene expression between the sexes. In normal females, XIST expression is dosage compensated between the sexes by silencing one of the two copies of chrX. However, among cancer patients, XIST was highly expressed in approximately 4% of male cancer samples, as well as absent in some female cancer samples [86]. This suggests that XIST dysregulation, including its expression in male cancers and its absence in female cancers, is a low-frequency but recurrent feature of human cancers. In male cancer samples, high expression of XIST and the phenomenon of XCI were seen in a variety of cancer types, including liver, brain, skin, lung, and thyroid cancers. In female hepatocellular carcinoma tissues, the expression of XIST RNA was significantly down-regulated, while the DNA methylation level of its promoter region was elevated. Further studies revealed that the TET2-YY1 complex could bind to the XIST promoter region and maintain its hypomethylated state, thus promoting XIST expression. This study provides new clues to the molecular mechanisms underlying sex differences in hepatocellular carcinoma and suggests that XIST may play an oncogene role in female hepatocellular carcinoma. In addition, XIST accelerates hepatocellular carcinoma progression by targeting the microRNA-320a/PIK3CA axis. Specifically, XIST negatively targets miR-320a, which negatively regulates the expression of PIK3CA, thereby affecting the proliferation, invasion, migration and apoptosis of hepatocellular carcinoma cells [87]. These findings may provide new targets for cancer treatment. Liu et al. demonstrated that the expression of XIST was significantly up-regulated in thyroid cancer tissues and cell lines (such as KAT18 and FTC133 cells). By knocking down the XIST in these cells, it was found that the cell proliferation ability decreased significantly, the tumor growth in vitro was inhibited, and the tumor volume and weight in the xenograft tumor model in vivo were also significantly reduced. Further mechanism research shows that XIST, as a molecular sponge of miR-34a, can release its inhibition on the downstream target gene MET by competitively binding with miR-34a, thus activating the MET-PI3K-AKT signaling pathway and promoting the proliferation of thyroid cancer cells and tumor growth. Therefore, this study clarified the function of XIST as a miRNA sponge in regulating tumor progression in thyroid cancer [88]. Yao et al. knocked down XIST in human glioblastoma stem cells (GSCs, respectively from male and female patients), and found that it significantly reduced the proliferation, migration and invasion ability of GSCs and induced apoptosis by releasing the “molecular sponge” inhibition of miR-152, and at the same time inhibited tumor growth and prolonged the survival time in nude mice, which was the first time to clarify that XIST played a role in promoting cancer in glioma stem cells as miR-152 sponge [89]. XIST/Xist RNA plays an important role in a variety of diseases, and its mechanism of action is complex, involving gene expression regulation, epigenetic changes, and other levels. With the in-depth study of XIST/Xist RNA, it may provide new targets and strategies for the treatment of these diseases in the future. Future perspectives In recent years, significant progress has been made in understanding how XIST/Xist RNA establishes chromosome-wide silencing, but there are still some uncharted waters to be solved. First, the role of XIST/Xist may be different in early as opposed to later stages of embryonic development, and its effects may vary across cell types. Understanding how XIST/Xist functions in different cell types and developmental stages, then, is a complex process. Secondly, studies have shown that inserting XIST into chromosome 21 through gene editing technology is expected to be used to treat Down syndrome. However, how to accurately introduce XIST/Xist into chromosome 21 is still a technical challenge [90]. Finally, there is growing evidence that XIST/Xist RNA is an important regulator of X chromosome dosage compensation in placental mammals and can play a key role in a number of sex-biased disorders. Therefore, a full understanding of XIST/Xist in molecular biology will facilitate the use of XIST/Xist as a diagnostic biomarker and therapeutic target for the treatment of gender-biased diseases. Taken together, the XIST/Xist study is not only crucial for understanding the mechanisms of sex determination and dosage compensation, but also provides new perspectives for exploring the roles of non-coding RNAs in human health and disease, and may open up new avenues for future drug development.